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T
oxoplasma gondii (Fig. 1) is a 
protozoan parasite that can 
be transmitted directly from 
cats to humans through fae-
cal contamination of food, 
or indirectly from cats to live-
stock and then to humans through 
undercooked meat. Around 30% of 
humans in the United Kingdom are 
infected, and as such, harbour dormant 
cysts in their brain, but few have overt 
symptoms of disease. Neurological 
disease can occur in these people if 
they become immunosuppressed (Fig. 
2). The possibility that apparently 
healthy people with infection are 
more likely to develop psychiatric 
disease, including schizophrenia and 
depression, is under investigation. 
Infection during pregnancy can cause 
abortion or foetal infection. Congenital 
disease can result in systemic, neuro-
logical and progressive eye disease. 
No vaccine exists for prevention of 
infection or disease and current drug 
treatments are not entirely effective.
100 years of T. gondii research
T. gondii (Fig. 1) was discovered about 
100 years ago in a rodent in North Africa 
by Nicolle and Manceaux, and later 
the same year in Brazil as an infec-
tion in a rabbit by Splendore. The 
protozoan was initially thought to be 
a new species of Leishmania (originally 
Leishmania gondii, but it was soon 
realized to be an entirely new entity). 
Its name was derived from the Greek 
words toxon (bow- or crescent-
shaped) and plasma (cell). Studies into 
the morphology of T. gondii by 
electron microscopy began in the 
1950s, and the complete life cycle 
with the identification of the feline 
family as the definitive host was only 
elucidated in the 1960s. Hutchison 
and his team from the University 
of Strathclyde in Glasgow played a 
crucial role in the discovery of the sexual cycle occurring in 
the intestinal tissue of the cat. Since then, T. gondii has become 
a model parasite to dissect host–pathogen relationships and 
the immune system.
 T. gondii was recognized as a human pathogen in the early 
1920s. Initial observations could not identify the parasite, 
but in 1939 the first cases of human toxoplasmosis were 
described. In the same year, Albert Sabin isolated T. gondii 
from two patients, one of which was the virulent type I 
RH strain, named after the patient’s initials and used in 
many laboratories worldwide to this day. Sabin and Harry 
Feldman developed a serological test in 1948, advancing 
diagnosis in humans dramatically. The severity of the disease 
during pregnancy was recognized in the early 1950s, with 
a detailed account of fatal toxoplasmosis cases in infants 
with hydrocephalus. Studies into congenital transmission 
elucidated that mother seroconversion during each 
trimester impacts on the severity of foetal infection, with 
primary infection during the first two trimesters the most 
damaging. Until the late 1960s, the diagnosis of congenital 
infection depended on seroconversion of the mother, but 
IgM detection in the umbilical cord greatly improved the 
diagnosis of congenital toxoplasmosis. Congenital disease is 
usually associated with post-natal brain disorders and ocular 
toxoplasmosis. The recognition of ocular toxoplasmosis, 
as a result of adult-acquired infection, was described by 
Reiger in 1951. The danger of T. gondii infection in immuno-
compromised patients was described in the late 1960s, but 
it was not until the 1980s that reactivation of toxoplasmosis 
was seen as critical if not treated in immunocompromised 
patients with chronic HIV infection (Fig. 3).
Epidemiology
The incidence of T. gondii infection varies considerably in 
humans according to geographical region. In the UK, the 
incidence has been reported as around 30%. In contrast, it is 
significantly greater in other European countries (e.g. France, 
80%; Austria, 50%). In these countries, antenatal screening 
is compulsory and in recent years a decrease in cases has 
been reported. High incidence in certain European countries 
has been attributed to differences in food preparation 
with the increased risk being thought to be due to eating 
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undercooked meat. In spite of the high level of infection in 
adults in some European countries, the occurrence of clinical 
disease is generally not perceived as a significant problem. 
This is at least partially due to the relatively avirulent nature of 
the strains of T. gondii causing infection in Europe. However, 
the general increased exposure in these countries poses a 
greater risk to expectant mothers and their foetuses. This is 
borne out by the statistics for congenital infection, which is 
reported as 1 in 2,000 births in Scotland, but as  high as 1 in 
500 births in France. Atypical and/or recombinant strains of 
T. gondii are associated with significant disease manifestations, 
including pulmonary involvement, splenomegaly and ocular 
disease in a number of non-European countries, most 
notably Brazil.
Disease
Disease outcome is dependent on a number of factors, 
including host genetics and immune status, parasite strain 
and mode of transmission. T. gondii infection in the immune-
competent host is generally not seen as a major problem. Mild 
’flu-like symptoms are experienced at the onset of infection 
which coincide with the presence of the rapidly dividing 
tachyzoite form of the parasite. As the immune system 
controls the tachyzoite stage, the parasite transforms to the 
bradyzoite form that encysts in various tissues throughout 
the body, predominantly in the brain (Fig. 2). These tissue 
cysts, in spite of being long-lived, are generally not perceived 
to cause overt disease. However, data are emerging that the 
cysts might contribute to psychiatric disease, including 
schizophrenia and depression. More subtle effects have been 
reported in humans, including reduced reaction times and 
personality changes.
 Immunocompromised people, such as those infected with 
HIV or undergoing immunosuppressive therapy, who are 
infected with T. gondii can develop severe systemic, ocular 
or most commonly neurological disease. This can be due to 
reactivation of a chronic infection or due to a newly acquired 
infection.
 The severity of congenital infection varies according to 
several factors, including time in gestation at which infection 
occurs, parasite strain and most probably host genetics. 
Foetuses infected early in gestation tend to be severely 
affected with overt neurological and ocular involvement 
at birth, whereas those infected late in gestation may not 
exhibit disease at birth. Essentially, all of these individuals 
will develop ocular lesions at some point in their life, 
usually during puberty. Again, the long-term management 
of these people is difficult due to the previously mentioned 
limitations in current chemotherapeutics.
Eukaryotic microbe dependent on 
‘prokaryotic’ biochemical processes
T. gondii is a eukaryotic pathogen that has been shaped 
through endosymbiotic events and evolution into a ‘mosaic’ 
made up of multiple components and processes derived 
from eukaryotic and prokaryotic organisms. Thus in 
addition to the commonly found mitochondrion (derived 
from an alphaproteobacterial endosymbiont), T. gondii has an 
apicoplast organelle, which was obtained through secondary 
endosymbiosis, most probably of a red alga. Consequently, 
T. gondii has a number of biochemical processes normally 
found in plants and or prokaryotes, including type II 
fatty acid biosynthesis, isoprenoid biosynthesis and haem 
biosynthesis. As these are generally absent, or evolutionarily 
distinct from the mammalian host, they have received a great 
deal of interest as potential antimicrobial targets. In addition, 
a number of drugs with known efficacy against T. gondii 
are now known to target prokaryote-like targets within the 
parasite. For example, drugs such as ciprofloxin, clindamycin 
and spiramycin target prokaryotic DNA replication.
Model apicomplexan  
and a tool to understand 
other important related 
pathogens
T. gondii is evolutionarily related to a 
number of other important human 
pathogens including Cryptosporidium 
and Plasmodium (the parasite that 
causes malaria). T. gondii has proved to 
be one of the most tractable organisms 
to study and has consequently shed 
light on these related pathogens. It has 
sometimes been used as a surrogate 
experimental system. The T. gondii 
research community has also developed 
some systems that have been directly 
applied to, or altered to work in other 
pathogen experimental systems. Thus 
it is now possible to perform targeted 
gene deletion, episomal expression, 
and inducible gene knock-down, and 
produce parasites containing reporter 
constructs, such as green fluorescent 
protein (GFP).
Immunological lessons
The immune response to T. gondii 
is complex and multifaceted. The 
organism has several pathogen-
associated molecular patterns (PAMPS) 
that interact with Toll-like receptors 
(TLRs) in the mammalian host to 
initiate an rapid immune response 
by innate immune cells, such as 
dendritic cells and macrophages. IL-
12 produced by these cells stimulates 
natural killer (NK) cells to produce 
IFNγ which in turn acts on infect-
ed cells to kill parasites through 
the induction of reactive nitrogen 
intermediates, or restrict their growth 
through selective depletion of 
tryptophan, which is required by the 
parasite. These initial interactions 
control parasite replication, but are 
not sufficient to provide complete 
protection – for this, T cell activation 
and expansion are required. T1 
helper cells, which also provide IFNγ, 
and cytolytic CD8 T cells, which 
can specifically recognize and kill 
infected cells, play an important role 
in mediating long-term immunity. 
Antibodies might also have a minor 
role in preventing invasion of the 
host cell.
Current treatments and  
future prospects
Most people receive antifolate 
therapy which normally comprises 
a combination of pyrimethamine 
and sulphadiazine. This is usually 
administered with folinic acid to 
reduce bone marrow toxicity. Several 
other therapies have been used, but 
none of these are able to eliminate the 
cystic stages. Targeting the ‘prokaryotic’ 
processes mentioned previously may 
offer better drugs.
Vaccine prospects
A vaccine has been sought for many 
years. Not surprisingly, studies have 
been technology-dependent (and 
arguably driven). Early studies used 
killed or homogenized parasites, or 
attempted attenuation. This was 
followed by crude extracts and then 
ever-increasingly enriched or purified 
parasite components. The advent of 
recombinant DNA technology allowed 
parasite proteins to be expressed 
and tested in experimental systems. 
Ultimately, synthetic peptides were 
tested in some systems. During this 
time, when technology allowed 
progressively more defined and pure 
antigenic components to be produced, 
it was noted that immunogenicity was 
markedly reduced. To some degree 
this instigated vaccine adjuvant 
research, but also encouraged people 
to contemplate viral delivery systems, 
naked DNA vaccination or a return to 
parasite attenuation. Notably, a tissue 
culture attenuated strain of T. gondii 
(S48) has been used as a commercial 
vaccine for livestock. Although 
such a vaccine would never be used 
in humans, a defined, rationally 
attenuated parasite produced through 
gene deletion techniques, resulting 
in auxotrophic mutants, has been 
very successful in murine models of 
infection.
 Looking to the future, vaccine 
prospects for humans are improving. 
Specifically, now the T. gondii genome 
is essentially fully sequenced, and 
all potential antigenic peptides are 
‘known’ and available to study. This 
information combined with ever more 
sophisticated predicative algorithms 
capable of predicting T cell epitopes 
and their interaction with various MHC 
alleles may allow a return to synthetic 
peptide vaccines with modern potent 
vaccine adjuvants. The challenge will 
be to produce a vaccine that copes with 
the polymorphisms in human MHC 
molecules at a population level and 
polymorphisms evident in antigenic 
epitopes of the different strains of 
T. gondii.
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